cium and blood pressure in healthy subjects, but does not aÂect the action of insulin. Background. Acute administration of parathyroid hormone (PTH ) causes vasodilation and blood pressure Key words: parathyroid hormone; blood pressure; eugdecrease in experimental animals. This eÂect contrasts lycaemic clamp; hypertension; hyperparathyroidism; with the putative role of secondary hyperparathyroidinsulin sensitivity; intracellular calcium ism in the pathogenesis of hypertension of patients with renal failure. Uraemia is characterized by insulin resistance and hyperinsulinaemia. We therefore investigated whether subacute administration of physiological Introduction doses of human 1,34-PTH aÂects blood pressure under conditions of controlled insulin levels (euglycaemic Chronically increased plasma intact parathyroid horclamp technique) in humans.
gated whether subacute administration of physiological Introduction doses of human 1,34-PTH aÂects blood pressure under conditions of controlled insulin levels (euglycaemic Chronically increased plasma intact parathyroid horclamp technique) in humans.
mone (PTH ) concentration and/or intracellular calMethods. In a double-blind cross-over design 10 cium concentration ([Ca2+] i ) may be of relevance in healthy male subjects received, on two occasions, in the genesis of high blood pressure. This hypothesis is random order, for 2 h, either a sham infusion or an based on observations that hypertension in uraemic infusion of 200 units of 1,34-PTH.
patients with secondary hyperparathyroidism is associResults. Mean ionized calcium concentration increased ated with increased PTH and intracellular calcium significantly (P<0.01) within the normal range during concentrations [1 ] . Further, in patients with primary euglycaemic hyperinsulinaemia, both with sham hyperparathyroidism a high prevalence of hypertension infusion (from 1.25±0.04 to 1.29±0.02 mmol/l ) and is found in association with increased [Ca2+] i [2,3]. with infusion of 1,34-PTH, but the increase was more
In this regard it is of interest that studies in rats marked with 1,34-PTH administration (from 1. 26 have shown that PTH has acute vasodilator and blood ±0.05 to 1.33±0.07). In addition, mean platelet pressure lowering eÂects, probably via an increase in intracellular calcium concentration (by fluorescence prostaglandin production and release [4, 5] . Neverspectroscopy) was unchanged with sham infusion theless, studies in humans and even studies in rats, ( 49.9±4.1 versus 50.3±5.0 nmol ), but increased signihave documented that PTH plays a (permissive?) role ficantly (P<0.05; paired t-test) after 1,34-PTH infusion in the blood pressure increase in diÂerent models of (from 49.8±5.0 to 52.8±5.8). The infusion of hypertension, e.g. spontaneously hypertensive rats, etc. 1,34-PTH resulted in a significant (P<0.01) increase [5] [6] [7] . So far, no firm evidence has been presented in mean MAP (from 84±5 to 88±5 mmHg) as comfrom intervention studies that blood pressure in pared with sham infusion ( 85±4 versus 86±4). The humans is specifically aÂected by PTH. intra-individual changes in intracellular calcium conPatients with renal failure are characterized by centration (D[Ca2+] i ) were significantly correlated to derangements of glucose metabolism, i.e. insulin resistthe changes in mean MAP (DMAP) (r=0.87, ance and concomitant hyperinsulinaemia [8-10 ]. Some P<0.001). In contrast to blood pressure, insulin sensitrecent studies suggested that this is due, at least in ivity was not aÂected by 1,34-PTH infusion (M-value: part, to increased PTH and/or [Ca2+] i [11-13 ]. Insulin 7.2±1.6 mg/kg per min) as compared with sham infuresistance is also commonly found in patients with sion (7.3±1.4).
primary hyperparathyroidism [14] . Insulin aÂects Conclusion. Subacute administration of physiological intracellular calcium [15, 16] and it is not known doses of parathyroid hormone under hyperinsulinwhether there is an interaction between PTH and aemic conditions significantly aÂects intracellular calinsulin with respect to intracellular calcium and blood pressure.
Blood samples for measurements of plasma glucose levels (euglycaemic hyperinsulinaemic clamp technique) in a were taken from a retrograde dorsal hand vein canula placebo-controlled study with or without administrathroughout the clamp at 5 min intervals. 
Participants
arterialized standard bicarbonate levels were taken at the start and at the end of each clamp from a third canula. In Ten healthy normotensive white male subjects (mean age addition, blood samples for measurements of insulin and 25±3 years, mean body mass index (BMI ) 22.4±2.0 kg/m2) phosphate levels were taken at the start and thereafter every were recruited. All were normotensive non-smokers who 30 min until the end of each clamp. Muscle blood flow of were within 10% of ideal body weight and took no medica-the leg was measured with occlusion plethysmography tion. Their family histories were negative for hypertension (Periquant 803A, Gutmann Medizin Elektronik GmbH, or metabolic diseases. At the beginning of the study they Germany) at the start and at the end of the clamp. Mean underwent a physical examination, routine chemical tests arterial blood pressure ( MAP) was measured automatically and urine analysis. Normal glucose tolerance according to (DinamapA, Critikon Inc., USA) at regular intervals before the WHO criteria was confirmed in all volunteers by a 100-g and during the clamp experiments. A urine collection was oral glucose tolerance test.
done during the clamp examinations in order to assess sodium, calcium and phosphate excretion.
Protocol
The protocol was approved by the Ethics Committee of the Measurements and calculations
University of Heidelberg. Written informed consent was given by all participants. A randomized double-blind cross-The amount of glucose infused to maintain euglycaemia (glucose infusion rate) was evaluated in the last 40 min of over design was used. The volunteers were instructed to adhere for the duration of the study to a diet standardized the clamp, i.e. after a steady state of glucose infusion was achieved. The glucose disposal rate (M-value) was calculated with respect to carbohydrate and NaCl content. They maintained constant body weight (±0.5%) for at least 4 weeks for this period in order to assess insulin sensitivity [ 17] .
Plasma insulin concentrations were measured enzymatically before and during the study; alcohol consumption was not allowed and physical activity was maintained at its usual ( ES 22A, Boehringer Mannheim, Germany) using an ELISA with monoclonal insulin antibodies (normal range: 30-level throughout the investigation. All volunteers were studied twice within an interval of 7 days under euglycaemic 150 pmol/l ). The intra-assay and interassay coeÃcient of variation in healthy subjects was 5.2% and 7.5% respectively. conditions. During a standard 2-h euglycaemic clamp the subjects received, in random order, either a sham infusion, Phosphate concentrations were measured with an autoanalyser (Hitachi 705A, Boehringer Mannheim, Germany); i.e. 50 ml of 0.9% NaCl solution ( Kochsalz 0.9A, Braun Melsungen AG, Germany) or 200 units of synthetic human whole blood ionized-calcium concentrations with an ionometer ( Ionometer EFA, Fresenius AG, Germany); and arteri-1,34-parathyroid hormone (ParatharA, Rhone-Poulenc Rorer Pharmaceutical Inc., USA) dissolved in 50 ml of 0.9% alized standard bicarbonate levels with a blood-gas analyser (AVL 990A, AVL, Switzerland ). Plasma intact PTH concenNaCl solution. In order to prevent adsorption of 1,34-PTH to the infusion line, 2 ml of the volunteer∞s own blood were trations were measured with an immunoradiometric assay (normal range: 12-60 ng/l [ 18] ). The intra-assay and interasadded to the infusion. The infusion rate ( 25 ml/h) and consequently the volume infused were the same with both say coeÃcient of variation in healthy subjects was 7.6% and 9.8%, respectively. infusion modalities. Both the volunteers and the investigator performing the clamp were blinded with respect to the type For the measurement of [Ca2+] i , two samples of 20 ml of citrated venous blood were drawn from the volunteers, of infusion. Urine was collected for 24 h by all volunteers on the day before the clamp experiments in order to assess without compression, in order to avoid platelet activation.
Platelets were separated from other cells immediately theresodium, calcium and phosphate excretion. All participants were admitted to the clinic at 8 p.m. on the day before the after by gradient centrifugation. None of the samples exhibited visual signs of red blood cell haemolysis or fibrin clamp experiments. On the morning of the next day a euglycaemic clamp experiment was performed in a quiet formation: the viability of thrombocytes was confirmed by the trypan-blue exclusion method. Thereafter the plateletroom from 8 a.m. to 10 a.m. after an overnight 12-h fast. The hyperinsulinaemic euglycaemic clamp-technique was rich plasma was incubated with the fluorescence dye Fura 2 (FURA 2-AMA, Sigma Chemie, Germany) in a water-bath used as described in detail elsewhere [17] . In brief, first a priming bolus infusion of 100 mU insulin/m2 per min for 30 min at 37°C in the dark. The platelet-rich sample was separated from the dye by passage through a Sepharose ( H-InsulinA, Hoechst AG, Germany) was given over 2 min. Thereafter the rate of infusion was gradually decreased to a 2B-CL column ( XK 16A, Pharmacia Biotech, Germany) at room temperature. The column was prepared with a solution constant rate of 40 mU/m2 per min. Plasma insulin levels were raised to about 600 pmol/l. In order to prevent adsorp-containing 145 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgSO 4 , 0.5 mmol/l Na 2 HPO 4 ; 10 mmol/l HEPES ( pH 7.4; tion of insulin to the infusion line, 2 ml of the volunteer's own blood was added to the insulin infusion. At 4 min after osmolality 300 mosmol ). Samples of 1 ml were pooled, the platelets counted and their concentration adjusted to the start of the insulin infusion a 20%-glucose infusion (Glucosteril 20%A, Fresenius AG, Germany) was started. 4.0×107/ml. The platelets were re-incubated in the above HEPES buÂer with CaCl 2 in order to achieve a calcium concentration in the solution of 1 mmol. The [Ca2+] i measurement was performed with a luminescence spectrofluorometer ( LS 50BA, Perkin-Elmer, UK ), while the platelets were continuously stirred in a quartz cuvette maintained at 37°C. Fluorescence was read at an emission wavelength of 510 nm and sequential excitation wavelengths of 340 and 380 nm. The cells were lysed with 0.1% Triton X-100 in order to obtain maximum fluorescence; minimal fluorescence was determined by adding EGTA. The cytosolic free calcium concentration ( [Ca2+] i ) was calculated according to the equation by Grynkiewicz et al. [ 19] 
, where R max stands for the ratio F340/380 after addition of Triton X-100, R min means the ratio F340/380 after addition of EGTA and K d is the dissociation constant of fura 2 for calcium (224 nmol/l ). The coeÃcient of variation of [Ca2+] i measurement in the same subjects was less than 8% as tested in five subjects. were compared using the t-test for paired samples. In addi-infusion. The increase was marked and significant with tion, intra-individual data at the start and at the end of each infusion of 1,34-PTH, however. Mean intracellular clamp were also compared using the paired t-test. Bonferroni calcium concentrations remained unchanged with sham correction was applied in order to account for multiple infusion, but a significant increase was documented was unchanged with placebo or PTH administration. Both, euglycaemia and hyperinsulinaemia during the clamps were similar with sham and with PTH infusion Results (Table 2 ). Intravenous administration of 1,34-PTH did not influence insulin sensitivity; the diÂerence in mean M-value between PTH and sham infusion was not The infusion of 1,34-PTH over a period of 2 h resulted in a significant increase in mean MAP, whereas MAP significant. As expected, mean plasma phosphate concentrations decreased significantly during euglycaemic remained unchanged with sham infusion ( Table 1) . The intra-individual changes of MAP with sham and hyperinsulinaemia. The decrease was similar with both infusion protocols. The mean intact PTH level was with PTH infusion are shown on Fig. 1 . Mean ionized calcium concentrations increased somewhat with sham significantly lower after sham and after 1,34-PTH MAP, mean arterial blood pressure; MBF, muscle blood flow; ion Ca2+, whole blood ionized calcium concentration; [Ca2+] i , platelet intracellular calcium concentration; PTH, plasma intact parathyroid hormone. 1P<0.05, 2P<0.01, intra-individual comparison of data at the start and at the end of the clamps; 3P<0.05, 4P<0.01, intra-individual comparison of data between sham and 1,34-PTH infusion. infusion; but the decrease was more marked after of Hulter et al. [23] who administered supraphysiological doses of human 1,34-PTH for 12 days to healthy 1,34-PTH infusion. Mean urinary sodium excretion during the clamps was not aÂected by 1,34-PTH subjects. The infusion of 1,34-PTH induced hypercalcaemia and in parallel a significant increase in blood infusion, whereas mean calcium excretion was significantly lower and phosphate excretion higher with PTH pressure. Both, hypercalcaemia and hypertension normalized after the infusion was stopped [23] . In our administration as compared with sham infusion ( Table 2 ) . study a dose of PTH was chosen that induced only a minor increase in ionized calcium concentration within The mean 24-h urinary sodium, calcium and phosphate excretions on the day before the clamp experi-the normal range; nevertheless a modest but significant increase in blood pressure was seen. This observation ments were comparable to those on the day before sham infusion (171±39, 4.9±1.4 and 24±4 mmol/ is in agreement with results of several experimental studies, which have shown that PTH potentiates the 24-h) and the day before infusion of 1,34-PTH ( 176±45, 4.9±2.0 and 23±6 mmol/24-h).
Statistical analysis
pressor-eÂect of calcium by enhancing its entry into vascular smooth muscle cells [5, 24] . There are good arguments that the acute vasodilator and blood presDiscussion sure lowering eÂects of PTH result from enhanced vascular prostaglandin production [4, 5] . This is in apparent contrast to the present (sub)acute study in A salient feature of the present study is the demonstrahumans and points to potential species diÂerences. In tion that subacute administration of physiological our volunteers plethysmographically measured leg doses of human 1,34-PTH increased blood pressure in muscle blood flow did not change significantly with healthy volunteers under euglycaemic conditions in the 1,34-PTH infusion. This observation is compatible presence of controlled circulating insulin levels. In with the notion that the increase in blood pressure parallel, a significant and consistent increase in ionized seems not to be mediated by vasoconstriction in the calcium concentration and in [Ca2+] i was observed skeletal muscle microvasculature. We cannot rule out with administration of PTH, and the increase in blood the possibility, however, that minor changes in muscle pressure was strongly correlated to changes in [Ca2+] i . blood flow were undetectable with plethysmography. This observation is not surprising, since changes in Further, the discrepancy between the animal data and [Ca2+] i are the final common pathway through which the present human data may potentially relate to many of the eÂects of parathyroid hormone are medidiÂerent contributions between species of the ated [5,12]. Our findings suggest that an increase in PTH/PTHrp and the novel PTH 2 receptor and/or to PTH levels and/or [Ca2+] i may be of relevance in the diÂerent coupling to adenylate cyclase and the PKC/Ca genesis of high blood pressure. This speculation is pathway, respectively. corroborated by observations that in uraemic patients
We controlled plasma insulin concentrations because with secondary hyperparathyroidism, as well as in of its known vasodilator eÂects [25 ] . It is interesting patients with essential hypertension and even in genetthat during sham infusion under conditions of the ically pre-hypertensive subjects, a positive correlation euglycaemic hyperinsulinaemic clamp, ionized calcium is found between blood pressure on the one hand and increased significantly while plasma phosphate (and intact PTH concentrations and [Ca2+] i on the other potassium) decreased, as has been shown previously in [1, [20] [21] [22] .
our laboratory [26 ] . This was associated with a signiThe prevalence of hypertension is known to be high ficant decrease of intact PTH concentration [26 ] . The in patients with primary hyperparathyroidism [2 ] . In line with these observations are data from the study latter is not an artefact resulting from circadian
